What is Invitae?
Headquartered in San Francisco, Invitae operates at the intersection of biotechnology and digital health. The company specializes in processing DNA-containing samples via in-home test kits, providing clinicians and patients with actionable insights derived from complex genetic data. By streamlining the translation of genomic information into clinical reports, Invitae has established itself as a critical infrastructure provider in the United States healthcare ecosystem, facilitating personalized treatment planning and early disease detection.
How much funding has Invitae raised?
Invitae has raised a total of $1.2B across 11 funding rounds:
Series F
$120M
Stock Offering
$116.8M
Share Placement
$73.5M
Debt
$40M
Stock Offering
$53.5M
Stock Offering
$196.7M
Debt
$291.2M
Stock Offering
$184M
Share Placement
$30M
Series F (2014): $120M supported by OrbiMed, Decheng Capital, Deerfield Management, Genesys Capital, Thomas McNerney & Partners, Wellington Management, Rock Springs Capital, Randy Scott, Genomic Health, Casdin Capital, Redmile Group, Perceptive Advisors, and The Broe Group
Stock Issuance/Offering (2015): $116.8M featuring Undisclosed
Share Placement (2017): $73.5M backed by Undisclosed
Debt (2018): $40M with participation from Oxford Finance
Stock Issuance/Offering (2018): $53.5M led by Undisclosed
Stock Issuance/Offering (2019): $196.7M supported by Undisclosed
Debt (2019): $291.2M featuring Undisclosed
Stock Issuance/Offering (2020): $184M backed by Undisclosed
Share Placement (2023): $30M, investors not publicly disclosed
Key Investors in Invitae
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation at various development stages.
Casdin Capital
An investment firm founded in 2011 that brings deep expertise and a long-term perspective to financing the next generation of life science and molecular information pioneers.
Thomas McNerney & Partners
A healthcare venture firm focused on investing in innovative life science and medical technology companies, providing growth capital to advance clinical development and product commercialization.
What's next for Invitae?
With the support of its latest strategic financing, Invitae is positioned to further optimize its diagnostic throughput and expand its reach within the precision medicine market. The company's trajectory suggests a continued focus on integrating advanced AI-driven analytics into its existing genomic intelligence framework. As the firm moves beyond its initial scaling phase, the focus will likely shift toward enhancing operational efficiencies and deepening its integration with clinical workflows, ensuring that its genetic testing services remain a cornerstone of modern patient care and therapeutic decision-making.
See full Invitae company page
